Need help navigating aged care? Explore our support services
Aged Care Home
Support at Home
Retirement Living
Finance & Placement Advice
Healthcare Equipment
Mobility and Equipment
Patient care equipment
Skin and wound Care
Safety and Security
Assessments
Assistive Technology
End of Life
Financial Services
Funerals
Placement Consultants
Advocacy
No results found
No results found
No results found
Advanced Filters
Distance (proximity)
Price Range
RAD (Refundable Accommodation Deposit) is a lump-sum payment for aged care homes. It is fully refundable when the resident leaves, as long as there are no outstanding fees.
Min RAD
Any
$250,000
$500,000
$750,000
$1,000,000
$1,500,000
$1,750,000
$2,000,000
Maximum RAD
Any
$250,000
$500,000
$750,000
$1,000,000
$1,500,000
$1,750,000
$2,000,000
Facility size
Based on how many beds the facilty has.
Any
Small
Medium
Large
Service Delivery
Services offered at a location or in a region
Any
On Site
Service Region
Features
Single rooms with ensuites
Respite beds
Extra service beds
Secure dementia beds
24/7 Registered nursing
Full or Partially government funded
Couples accommodation
Facility has pets
Non-dedicated respite
Palliative care
Partner considered without ACAT
Secure garden
Transition care
Cafe/Kiosk
Chapel/Church
Hairdressing Salon
Facility Owned Transport
Single Rooms
Rooms with ensuites
Registered nursing
Non secure dementia care
Diversional therapy
Medication supervision
Respite care
Secure access
Small pets considered

Australian neuroscientists claim pill may prevent onset of Alzheimer’s

Posted
by DPS
<p>Pill that may prevent Alzheimer’s</p>

Pill that may prevent Alzheimer’s

Australian neuroscientists claim pill may prevent onset of Alzheimer’s

A team of neuroscientists at the Mental Health Research Institute of Victoria is working with the pharmaceutical company Prana Biotechnology to develop a new drug called PBT2 that could delay the onset of the degenerative symptoms of Alzheimer’s disease, which is now being diagnosed in Australia at a rate of 1,000 new cases per week.

The drug works by blocking the interaction between amyloid beta protein, which is the abnormal protein produced in patients with Alzheimer’s disease in the brain, and metal ions in the brain, and in particular copper.

It also prevents the precipitation of the protein in the brain and thereby the production of large plaques of abnormal protein that interfere with normal nerve conduction.
About 90 people over the age of 60 and in the early stages of Alzheimer’s will take part in a controlled experiment in Sweden for at least a year followed by trials in Australia.

Alzheimer’s Australia Executive Director in Victoria, Lynette Moore, says even if clinical trials are successful, the release of such a pill onto the market could take another five to 10 years.

Read next

Sign up or log in with your phone number
Phone
Enter your phone number to receive a verification notification
Aged Care Guide is endorsed by
COTA logo
ACIA logo